Alaunos Therapeutics (TCRT)
Preclinical developer of ALN1003, an oral small molecule for obesity.
Something off on this page? Send us feedback.
Develops ALN1003, a preclinical oral small molecule for obesity and related metabolic disorders, while receiving limited royalty income from legacy oncology asset darinaparsin. Its model relies on external financing, consultants, CDMOs and eventual regulatory clearance rather than product sales.
Develops ALN1003, an investigational oral small molecule for obesity and related metabolic disorders. The active program is preclinical, testing a non-hormonal, non-incretin approach to insulin resistance, adipose signaling and hepatic lipid metabolism; it had not entered human trials.
Operates from Fort Lauderdale with a minimal internal team and consultants, outsourcing active-pharmaceutical-ingredient and drug-product work to a limited set of CDMOs. The former oncology business survives mainly as a small royalty interest from Japanese licensee Solasia's darinaparsin sales, while legacy TCR-T assets have not found a buyer or licensee.
Depends on new financing, regulatory clearance for human testing and external manufacturing partners; no current candidate has an IND or an issued obesity-program patent.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $124.0K · Total debt $0 · Total assets $1.5M · Shareholders' equity $652.0K
- Revenue
- $0
- Operating income
- −$952.0K
- Net income
- −$952.0K
No dividends on record.
| Institutions29 holders · as of Mar 31, 2026 | 4.96% | 125.9K shares | |
| Insiders6 holders · as of Aug 11, 2026 | 20.71% | 526.1K shares | |
| Otherremainder | 74.33% | 1.89M shares |
2.54M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Robert W. Postma1Insiderdirector | 9.03% | 199,796 | 13Dfiled Jul 27, 2026 ↗ |
Price AdrianInsider | 7.44% | 189,061 | 13Dfiled Mar 5, 2026 ↗ |
Jaime VieserInsiderdirector | 1.88% | 47,642 | Form 4filed Jul 27, 2026 ↗ |
Holger WeisInsiderofficer: CEO | 1.00% | 25,483 | Form 4filed Aug 11, 2026 ↗ |
Michael Allen JermanInsiderdirector | 0.94% | 23,759 | Form 4filed Jul 27, 2026 ↗ |
| See all 25 → | |||
- Robert W. Postma's transaction reports restate only vehicles that traded; the 2025 ownership statement (199.8K) plus the 29.6K net shares acquired since is used instead.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Novo Nordisk (ADR)
Marketed Wegovy franchise sets the obesity-treatment benchmark.
- Eli Lilly
Marketed Zepbound franchise leads injectable obesity care.
- Amgen
MariTide Phase 3 program challenges future obesity positioning.
- Pfizer
Acquired Metsera pipeline adds broad obesity-development threat.
- Viking Therapeutics
VK2735 rivals across oral and injectable obesity treatment.
- Structure Therapeutics (ADR)
Oral small-molecule pipeline overlaps most closely on modality.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics | $1.69 | +1.81% | $4.1M | — | — | 1,359.5 | −25.0% |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Eli Lilly | $1,165.91 | +0.56% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Amgen | $445.00 | +0.49% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| Structure Therapeutics (ADR) | $47.80 | +0.06% | $2.75B | — | — | — | — |
| Median | 32.9 | 18.9 | 5.2 | +6.1% |